Results 171 to 180 of about 24,686 (257)

Glucose Transporter 1 in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
As the quintessential facilitator of basal glucose uptake, glucose transporter 1 (GLUT1) is indispensable for maintaining systemic energy homeostasis. This graphical abstract delineates the multidimensional landscape of GLUT1 in normal physiology. It highlights its tissue‐specific metabolic roles—from fueling erythrocytes and fetal development to ...
Yi Tai, Zhihao Chen, Yuping Zhu, Weidong Han   +3 more
wiley   +1 more source

Methylglyoxal and Advanced Glycation End Products (AGEs): Targets for the Prevention and Treatment of Diabetes-Associated Bladder Dysfunction? [PDF]

Biomedicines
Oliveira AL, de Oliveira MG, Mónica FZ, Antunes E.   +3 more
europepmc   +1 more source

Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 3, Page 356-366, August 2026.
In this territory‐wide cohort study, improving glycemic control can be observed regardless of cirrhosis status. Oral antidiabetic medication was more often used in the non‐cirrhosis group, and insulin was preferred in patients with decompensated cirrhosis, who exhibited an increasing incidence of hypoglycemia over the years and need individualized ...
Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip   +6 more
wiley   +1 more source

Association between endothelial function and skin advanced glycation end-products (AGEs) accumulation in a sample of predominantly young and healthy adults. [PDF]

Cardiovasc Diabetol
Fewkes JJ, Dordevic AL, Murray M, Williamson G, Kellow NJ.   +4 more
europepmc   +1 more source

Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6576-6583, August 2026.
ABSTRACT Aims Achieving optimal glycaemic control remains a burden for many people with diabetes on intensive insulin treatment. The MELISSA trial aims to clinically validate the artificial intelligence (AI)‐based MELISSA system to support people with Type 1 diabetes on multiple daily insulin injections (MDI) with personalised insulin dose ...
Elisabeth J. den Brok, Cecilie H. Svensson, Mikkel T. Olsen, Nefeli M. Dimitropoulou, Sander M. J. van Kuijk, Maria Panagiotou, Lubnaa Abdur Rahman, Stephan Proennecke, Peter R. Mertens, Stavros Athanasopoulos, Cassy F. Dingena, Konstantinos Makrilakis, Stavroula Mougiakakou, Ulrik Pedersen‐Bjergaard, Bastiaan E. de Galan, on behalf of the MELISSA consortium   +15 more
wiley   +1 more source

Clinical Implications and Research Progress of Salivary Biomarkers for Endocrine and Metabolic Disorders

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6561-6575, August 2026.
ABSTRACT Aims Similar to blood, saliva contains a broad range of biomarkers and may offer a non‐invasive, repeatable specimen for endocrine and metabolic assessment. This review aims to synthesise and evaluate recent advances in the clinical translation of salivary biomarkers, while providing a critical assessment of the diagnostic reliability and ...
Chuyan Yu, Jiaying Ni, Qian Dou, Hang Su, Ziyi Zhang, Xiaojing Ma, Qing Dai, Jian Zhou   +7 more
wiley   +1 more source

Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial. [PDF]

Reprod Sci
Ozdemir M, Mumusoglu S, Bilgic P.
europepmc   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, Volume 300, Issue 2, Page 131-152, August 2026.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1‐Mediated Glucotoxic Stress in Diabetic Kidney Disease

The FASEB Journal, Volume 40, Issue 14, 31 July 2026.
Hyperglycemia upregulates CTRP1 and SGLT2 in renal tubular cells, promoting glucose influx, CTRP1‐mediated glucotoxic stress, and tubular senescence in diabetic kidney disease. In the experimental model, SGLT2 inhibition with dapagliflozin was associated with reduced glucose uptake, attenuation of tubular senescence, suppression of CTRP1‐related ...
Lina Gu, Buhui Liu, Lei Zhang, Jing Zhao, Weiming He, Hong Lang, Wei Sun   +6 more
wiley   +1 more source

Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength. [PDF]

Elife
Leanza G, Cannata F, Faraj M, Pedone C, Viola V, Tramontana F, Pellegrini N, Vadalà G, Piccoli A, Strollo R, Zalfa F, Beeve AT, Scheller EL, Tang SY, Civitelli R, Maccarrone M, Papalia R, Napoli N.   +17 more
europepmc   +1 more source